Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the Oversold Growth Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) since the company released its fiscal second quarter 2025 results.

The company posted $178.49 million in revenue, down 10.61% year-over-year and below expectations by $10.15 million. On the bright side, the EPS of negative $0.33 topped estimates by $0.15. Management noted that they are proud of the FDA approval of EMPAVELI for two rare kidney diseases, including C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. This is because the approval marked the first FDA-approved treatment for these conditions in patients aged 12 and older.

Despite this, Wall Street has a mixed opinion about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Earlier on August 6, Tazeen Ahmad from Band of America Securities reiterated a Hold rating on the stock with a $26 price target. The analyst acknowledged the FDA approval of EMPAVELI as a key milestone. However, he noted that the market is fragmented with payor access challenges that may slow the drug’s launch. He added that the patient group is small and possibly underdiagnosed, limiting broad uptake. Moreover, the physician’s choice between Empaveli and competitors like Fabhalta adds uncertainty to its adoption.

More recently, on September 7, Steven Seedhouse from Cantor Fitzgerald reiterated a Buy rating on the stock with a $40 price target.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) develops and commercializes therapies that target the complement system to treat diseases with unmet medical needs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.